ADAMTS13 and hepatocellular carcinoma: In HCC, ADAMTS13 and VWF have been shown to be potentially useful biomarkers for the prognosticating treatment response of sorafenib [153], hepatic artery infusional chemotherapy [154] and liver resection [155].